Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair

被引:147
作者
Amanat, Negin
McDonald, Michelle
Godfrey, Craig
Bilston, Lynne
Little, David
机构
[1] Univ Sydney, Sch Aerosp Mech & Mechatron Engn, Sydney, NSW 2006, Australia
[2] Univ New S Wales, Prince Wales Med Res Inst, Randwick, NSW, Australia
[3] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia
[4] Childrens Hosp, Westmead, NSW, Australia
关键词
bisphosphonates; fracture healing; bioMechanical testing; autoradiography; animal model;
D O I
10.1359/JBMR.070318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We hypothesized that ZA treatment would bolster fracture repair. In a rat model for closed fracture healing, a single dose of ZA at 0, 1, or 2 wk after fracture significantly increased BMC and strength of the healed fracture. Delaying the dose (1 or 2 wk after fracture) displayed superior results compared with dosing at the time of fracture. Introduction: Bisphosphonates are known to increase bone strength and thus the resistance to fracture by decreasing osteoclastic bone resorption. These properties may enable bisphosphonates to also increase the strength of fracture repair. Zoledronic acid (ZA) is a potent bisphosphonate with a high affinity for bone mineral, allowing bolus intraveous dosing in a range of indications. In this study, we examined the application of bolus dose ZA in endochondral fracture repair. Materials and Methods: Carbon-14 labeled ZA was used in a closed rat fracture model. Rats were divided into five treatment groups (n = 25 per group): saline control, local ZA (0.01 mg/kg), and three systemic bolus ZA groups (0.1 mg/kg) with different administration times: at fracture, 1 wk after fracture, and 2 wk after fracture. Rats were killed 6 wk postoperatively. Postmortem analyses included radiography, QCT, mu CT, biomechanical testing, scintillation counting, autoradiography, and histology. Results: Single-dose systemic ZA administration significantly increased callus volume, callus BMC, and mechanical strength. Perioperative treatment increased mechanical strength by 30% compared with controls (p < 0.05). Administering the systemic dose at 1 or 2 wk after fracture further increased mechanical strength compared with controls by 44% and 50%, respectively (p < 0.05). No significant differences in mechanical parameters were seen with local injection at the dose studied. Autoradiographic analysis indicated that ZA binds significantly to bone that is present at the time of administration. ZA quantification indicated that delayed administration significantly increased the uptake efficiency in the callus. Histological and RCT analysis showed that ZA treated calluses had a distinctive internal structure consisting of an intricate network of retained trabecular bone. Conclusions: The timing of a single systemic dose of ZA plays an important role in the modulation of callus properties in this rat fracture model; delaying the single dose produces a larger and stronger callus.
引用
收藏
页码:867 / 876
页数:10
相关论文
共 32 条
[1]   Clodronate increases mineralization of callus after Colles' fracture -: A randomized, double-blind, placebo-controlled, prospective trial in 32 patients [J].
Adolphson, P ;
Abbaszadegan, H ;
Bodén, H ;
Salemyr, M ;
Henriques, T .
ACTA ORTHOPAEDICA SCANDINAVICA, 2000, 71 (02) :195-200
[2]   A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair [J].
Amanat, N ;
Brown, R ;
Bilston, LE ;
Little, DG .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2005, 23 (05) :1029-1034
[3]  
Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
[4]   Zoledronic acid improves the mechanical properties of normal and healing bone [J].
Bilston, LE ;
Little, DG ;
Smith, NC ;
Williams, P ;
Briody, J .
CLINICAL BIOMECHANICS, 2002, 17 (9-10) :716-718
[5]  
BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
[6]   Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases [J].
Chen, TL ;
Berenson, J ;
Vescio, R ;
Swift, R ;
Gilchick, A ;
Goodin, S ;
LoRusso, P ;
Ma, PM ;
Ravera, C ;
Deckert, F ;
Schran, H ;
Seaman, J ;
Skerjanec, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1228-1236
[7]  
Doggrell Sheila A, 2002, Expert Opin Pharmacother, V3, P1007, DOI 10.1517/14656566.3.7.1007
[8]   A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair [J].
Einhorn, TA ;
Majeska, RJ ;
Mohaideen, A ;
Kagel, EM ;
Bouxsein, ML ;
Turek, TJ ;
Wozney, JM .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2003, 85A (08) :1425-1435
[9]  
Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
[10]  
Goodship A E, 1994, Ann Oncol, V5 Suppl 7, pS53